Back
Aquestive Therapeutics Quote, Financials, Valuation and Earnings
Sponsored
AQST
Sponsored
"The Next Apple?" - Mode's Growth Story is Turning Heads
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
63
AQST
Aquestive Therapeutics
Last Price:
5.20
Seasonality Move:
11.7%
7 Day Trial
ALL ACCESS PASS
$
7
How this hedge fund manager trades weekly options
Claim your free training on trading weekly optionsAquestive Therapeutics Price Quote
$5.20
+0.25 (+5.05%)
(Updated: September 19, 2024 at 6:55 PM ET)
Aquestive Therapeutics Key Stats
Buy
63
Aquestive Therapeutics (AQST)
is a Buy
Day range:
$4.76 - $5.11
52-week range:
$1.25 - $6.23
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
6.29
P/B ratio:
0%
Volume:
1.1M
Avg. volume:
1.2M
1-year change:
219.35%
Market cap:
$450.7M
Revenue:
$50.6M
EPS:
$-0.36
How Much Does Aquestive Therapeutics Make?
-
How Much Are Aquestive Therapeutics's Sales Annually?
AQST Revenues are $50.6M -
How Much Profit Does Aquestive Therapeutics's Make A Year?
AQST net income is -$7.9M
Is Aquestive Therapeutics Growing As A Company?
-
What Is Aquestive Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.52% -
What Is Aquestive Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Aquestive Therapeutics Stock Price Performance
-
Did Aquestive Therapeutics Stock Go Up Last Month?
Aquestive Therapeutics share price went up by 16.75% last month -
Did AQST's Share Price Rise Over The Last Year?
AQST share price rose by 219.35% over the past 1 year
What Is Aquestive Therapeutics 52-Week High & Low?
-
What Is Aquestive Therapeutics’s 52-Week High Share Price?
Aquestive Therapeutics has traded as high as $6.23 over the past 52 weeks -
What Is Aquestive Therapeutics’s 52-Week Low Share Price?
Aquestive Therapeutics has traded as low as $1.25 over the past 52 weeks
Aquestive Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Aquestive Therapeutics?
-
How Much Debt Does Aquestive Therapeutics Have?
Total long term debt quarterly is $30M -
How Much Cash Does Aquestive Therapeutics Have?
Cash and short term investments quarterly total is $89.9M -
What Is Aquestive Therapeutics’s Book Value Per Share?
Book value per share is -0.39
Is Aquestive Therapeutics Cash Flow Positive?
-
What Is AQST Cash Flow From Operations?
Cash flow from operations (TTM) is -$24.7M -
What Is Aquestive Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $92.3M -
What Is Aquestive Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$231K
Aquestive Therapeutics Return On Invested Capital
Data Unavailable
Aquestive Therapeutics Earnings Date & Stock Price
-
What Is Aquestive Therapeutics's Stock Price Today?
A single share of AQST can be purchased today for 4.95 -
What Is Aquestive Therapeutics’s Stock Symbol?
Aquestive Therapeutics trades on the nasdaq under the ticker symbol: AQST -
When Is Aquestive Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Aquestive Therapeutics is scheduled on November 6, 2024 -
When Is AQST's next ex-dividend date?
Aquestive Therapeutics's next ex-dividend date is September 20, 2024 -
How To Buy Aquestive Therapeutics Stock?
You can buy Aquestive Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Aquestive Therapeutics Competitors
-
Who Are Aquestive Therapeutics's Competitors?
Below is a list of companies who compete with Aquestive Therapeutics or are related in some way:
Aquestive Therapeutics Dividend Yield
-
What Is AQST Dividend Yield?
Aquestive Therapeutics’s dividend yield currently is 0% -
What Is Aquestive Therapeutics’s Payout Ratio?
Aquestive Therapeutics’s payout ratio is 0% -
When Did Aquestive Therapeutics Last Pay A Dividend?
The latest dividend pay date is September 20, 2024 -
What Is Aquestive Therapeutics’s Dividend Per Share?
Aquestive Therapeutics pays a dividend of $0.00 per share
Aquestive Therapeutics Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | 88.33% |
Revenue: | 51.79% | 62.35% |
Analyst Recommendations
Buy Recommendations: | 4 |
---|---|
Hold Recommendations: | 0 |
Sell Recommendations: | 0 |
Price Target: | 9.06 |
Upside from Last Price: | 83.08% |